We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Delaware Court Gives Go Ahead on More Than 70,000 Zantac Trials 

Delaware Court Gives Go Ahead on More Than 70,000 Zantac Trials 

June 6, 2024

More than 70,000 Zantac cases may go to trial following Delaware Superior Court Judge Vivian Medinilla’s order allowing plaintiffs’ expert witnesses to testify in court that the drug may cause cancer.

Defendants Boehringer Ingelheim, GSK, Pfizer and Sanofi challenged ten expert witnesses and Emery Pharma, a contract research laboratory.

Judge Medinilla explained that the court was ruling on the parties’ competing motions to exclude expert testimony under Rule 702 of the Delaware Rules of Evidence. In her decision, she said that “It would be improper to simply dismiss these experts as ‘poseurs or witnesses for hire. They are serious scientists,’” adding that “Any remaining challenges will be made at trial via cross-examination and introduction of counter evidence.

To read the whole story, click here.

Related Topics

Drugs Commercial Operations

    Upcoming Events

    • 13Jun

      FDA in 2024 and Beyond: What Election-Year Changes Mean for Your Business

    • 20Jun

      Inspection Readiness for EU GMP Annex 1 – Manufacture of Sterile Medicinal Products

    • 11Jul

      Postmarket Surveillance in the Real World: The FDA’s Perspective on RWD/RWE

    • 18Jul

      AI/ML in Medical Devices: U.S. and EU Regulatory Perspectives

    • 21Oct

      MAGI@home Clinical Research Conference 2024

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • FDA Worries MDMA Makes Patients Feel So Good That Trials Might Be Compromised

    • Several Potential Failure Points Leads to OptumHealth Infusion Pump Class I Recall

    • Delaware Court Gives Go Ahead on More Than 70,000 Zantac Trials 

    • Another Recall for Philips Ventilators — With Reports of 10 Injuries, 7 Deaths

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing